BRIEF

on VALBIOTIS (EPA:ALVAL)

Valbiotis awarded for its cardiometabolic health solutions

Stock price chart of VALBIOTIS (EPA:ALVAL) showing fluctuations.

The French laboratory Valbiotis, specializing in cardiometabolic health, has been awarded "Best Pharma Product 2027" for its ValbiotisPRO® Cholesterol and ValbiotisPRO® Metabolic Health innovations. These awards, based on independent consumer testing, confirm the effectiveness of these products, developed after ten years of research.

In France, the cholesterol supplement market is undergoing regulatory changes, creating new opportunities. Thanks to its red yeast rice-free formulation, ValbiotisPRO® Cholesterol stands out. At the same time, the metabolism segment is experiencing strong growth, reinforcing the relevance of ValbiotisPRO® Metabolic Health.

These distinctions enhance Valbiotis' visibility and credibility with pharmacies and consumers, consolidating its commercial strategy and position in the cardiometabolic health market.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALBIOTIS news